Observational Disease Registry of Patients Treated with
Systemic Mold-Active Triazoles
This is an observational research study of treatment that is usually given patients who have been diagnosed with an invasive fungal infection or patients who are at risk and are being treated to prevent an invasive fungal infection. Information from medical records is used to learn more about how these patients are treated and how they respond to treatment. It is thought that collecting this information may help researchers and doctors to determine the best treatment options and improve patient care for people who are at risk for fungal infections, or who have invasive fungal infections.
Immune compromised patients at risk for fungal infection
Patients with fungal infections
Patients must be taking or will soon be taking a target antifungal drug: voriconazole (VFEND), isavuconazium sulfate (Cresemba), or posaconasole (Noxafil).
Patients must be 18 or older
Patients can't be in a study with an investigational antifungal drug
18 - 89
Healthy Volunteers Needed
Duration of Participation
Patients will be followed until 90 days after your last dose of antifungal medication.
Knight Cancer Intake Center: (503)494-7999
Clinical Trials Information Line: (503)494-1080 or email@example.com
Astellas Pharma Global Development, Inc.